Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D P Kelsen

Showing results (31-40 of 129) with videos related to

Pageof 13
Sort By:
Seminars in Oncology|June 1, 1995
Paclitaxel in the treatment of carcinoma of the esophagusJ A Ajani, D H Ilson, K Daugherty, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 24, 2007
Systemic chemotherapy does not increase the risk of gastrointestinal perforationT R Asmis, M Capanu, D P Kelsen, et al.
Investigational New Drugs|November 1, 1992
Phase II trial of edatrexate in patients with advanced pancreatic adenocarcinomaE S Casper, G K Schwartz, B Johnson, et al.
Cancer Genetics and Cytogenetics|June 1, 1995
Cytogenetics of gastric and esophageal adenocarcinomas. 3q deletion as a possible primary chromosomal changeP H Rao, S Mathew, D P Kelsen, et al.
Cancer|November 1, 1980
Pharmacokinetics of gallium nitrate in manD P Kelsen, N Alcock, S Yeh, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 14, 2007
Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancerD H Ilson, R G Wadleigh, L P Leichman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1991
Lack of efficacy of high-dose leucovorin and fluorouracil in patients with advanced pancreatic adenocarcinomaJ Crown, E S Casper, J Botet, et al.
Cancer Chemotherapy and Pharmacology|May 10, 2000
Selective inhibition of cyclooxygenase-2 enhances mitomycin-C-induced apoptosisC T Hsueh, C F Chiu, D P Kelsen, et al.
Cancer Journal (Sudbury, Mass.)|November 9, 2000
A multi-institutional phase II study of BMS-182248-01 (BR96-doxorubicin conjugate) administered every 21 days in patients with advanced gastric adenocarcinomaJ A Ajani, D P Kelsen, D Haller, et al.
Cancer|August 1, 1990
Targeted cytogenetic analysis of gastric tumors by in situ hybridization with a set of chromosome-specific DNA probesH van Dekken, J G Pizzolo, D P Kelsen, et al.
Pageof 13

Showing results (31-40 of 129) with videos related to

Sort By:
Pageof 13
Seminars in Oncology|June 1, 1995
Paclitaxel in the treatment of carcinoma of the esophagusJ A Ajani, D H Ilson, K Daugherty, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 24, 2007
Systemic chemotherapy does not increase the risk of gastrointestinal perforationT R Asmis, M Capanu, D P Kelsen, et al.
Investigational New Drugs|November 1, 1992
Phase II trial of edatrexate in patients with advanced pancreatic adenocarcinomaE S Casper, G K Schwartz, B Johnson, et al.
Cancer Genetics and Cytogenetics|June 1, 1995
Cytogenetics of gastric and esophageal adenocarcinomas. 3q deletion as a possible primary chromosomal changeP H Rao, S Mathew, D P Kelsen, et al.
Cancer|November 1, 1980
Pharmacokinetics of gallium nitrate in manD P Kelsen, N Alcock, S Yeh, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 14, 2007
Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancerD H Ilson, R G Wadleigh, L P Leichman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1991
Lack of efficacy of high-dose leucovorin and fluorouracil in patients with advanced pancreatic adenocarcinomaJ Crown, E S Casper, J Botet, et al.
Cancer Chemotherapy and Pharmacology|May 10, 2000
Selective inhibition of cyclooxygenase-2 enhances mitomycin-C-induced apoptosisC T Hsueh, C F Chiu, D P Kelsen, et al.
Cancer Journal (Sudbury, Mass.)|November 9, 2000
A multi-institutional phase II study of BMS-182248-01 (BR96-doxorubicin conjugate) administered every 21 days in patients with advanced gastric adenocarcinomaJ A Ajani, D P Kelsen, D Haller, et al.
Cancer|August 1, 1990
Targeted cytogenetic analysis of gastric tumors by in situ hybridization with a set of chromosome-specific DNA probesH van Dekken, J G Pizzolo, D P Kelsen, et al.
Pageof 13